Belgian RWE Initiative Proposes Actions To Support HTA/Payer Decisions
Focus Is On Special Challenges Posed By Highly Innovative Technologies
A new initiative by the Belgian health care payer proposes action points for a range of stakeholders to help develop real-world evidence that can inform HTA/payer decision making for highly innovative technologies.
You may also be interested in...
Five new drugs have been recommended for EU approval at the latest meeting of European Medicines Agency’s drug evaluation committee.
The European Commission has set aside, for now, concerns expressed by member states regarding the scope of medicines subjected to additional monitoring requirements.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.